DelveInsight's Sarcopenia Market Insights report includes a comprehensive understanding of current treatment practices, ...

Scholar Rock's Apitegromab excels in Phase 2 trials, aiding muscle preservation with Tirzepatide. Click here to read why I ...

While the results were an important proof point for so-called anti-myostatin drugs, Scholar Rock executives indicated the ...

Myostatin inhibition is a very safe mechanism for weight loss and muscle preservation, and patients typically have no adverse effects, says Dr. Martin Brenner, the CEO at iBio.

SRK-439 is a novel, preclinical, investigational myostatin inhibitor that has high in vitro affinity for pro- and latent myostatin and maintains myostatin specificity (i.e., no GDF11 or Activin-A ...

The muscle protein – myostatin – acts as the body's natural brake on muscle growth. Working with mice, the researchers found that lowering myostatin levels delayed puberty and reduced fertility.

Aktien » Nachrichten » IBIO AKTIE » iBio, Inc.: iBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio.

iBio, Inc., an innovator in precision antibody immunotherapies, announced the expansion of its cardiometabolic and obesity treatment program by in-licensing a long-acting anti-myostatin antibody ...

Building on the success of the anti-Myostatin program, iBio Launches New Program Featuring Myostatin + Activin A Bispecific Antibody Designed to Promote Weight Loss, Prevent Muscle Loss and Weight ...

When I read my first novel about Jack Reacher, a larger-than-life character created by British author Lee Child, I was struck by several things. First, he was huge, at 6 ...

Etzer Darout, an analyst from BMO Capital, has initiated a new Buy rating on Scholar Rock Holding (SRRK). Etzer Darout’s buy rating for Sc ...